Clinical implication of SGLT2 inhibitors in type 2 diabetes.

Clinical implication of SGLT2 inhibitors in type 2 diabetes.

Item
http://www.wikidata.org/entity/Q38221980
Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study.Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled StudyAn overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patientsSafety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?Past and current perspective on new therapeutic targets for Type-II diabetes.Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia.
P2860

Clinical implication of SGLT2 inhibitors in type 2 diabetes.

Item
http://www.wikidata.org/entity/Q38221980
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
@en
type
label
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
@en
prefLabel
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P921
P356
P1433
P1476
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P921